1. The composition of the cancer vaccine, including expressing the antigen (s) of cancer cells, fillers, at the discretion of the adjuvant, where the specified antigen (these antigens) is expressed (expressed) upon contact of the cancer cell with the p38 inducer and where the specified expressed antigen (s) are specific for the allogeneic organ / tissue to which these cancer cells belong. 2. The composition of claim 1, wherein the amount of cancer cell expressing antigen (s) is from 10 to 10.3. The composition of claim 1, which, when administered to a mammal, elicits a cellular immune response specific for the tissue / organ to which the cancer cells belong. The composition of claim 1, which, when administered to a mammal, elicits a humoral immune response specific for the tissue / organ to which the cancer cells belong. The composition of claim 1, wherein the adjuvant is Mycobacterium w.6. The composition of claim 1, wherein the cancer cells are obtained from a patient and / or from a cell vault. A method for treating cancer in a mammal, comprising administering to the mammal a therapeutically effective amount of a composition as claimed in claim 1.8. The method of claim 7, wherein the cancer is represented by homologous or heterologous cells. The method of claim 7, wherein the therapeutic vaccine composition comprises cancer cells obtained from the same or another mammal. The method of claim 7, wherein the route of administration is selected from parenteral routes. The method according to claim 7, where the preferred route of administration is intradermal.1. Композиция раковой вакцины, включающая экспрессирующие антиген(ы) раковые клетки, наполнители, по усмотрению адъювант, где указанный антиген (указанные антигены) экспрессируется (экспрессируются) при контакте указанной раковой клетки с индуктором p38 и где указанные экспрессируемые антиген (антигены) специфичны для аллогенного органа/ткани, к которым принадлежат указанные раковые клетки.2. Композиция по п.1, г
